Table 3.
Signaling pathway enrichment analysis of downstream genes’ function in CML patients.
| Pathway | Name | Count | Genes | p-value |
|---|---|---|---|---|
| hsa05200 | Pathways in cancer | 9 | BCR, SMO, CCND1, MYC, BCL2, ABL1, BAX, MMP9, BCL2L1 | 2.79E-06 |
| hsa05206 | MicroRNAs in cancer | 7 | CCND1, IRS1, MYC, BCL2, ABL1, IRS2, MMP9 | 5.96E-05 |
| hsa05161 | Hepatitis B | 6 | PCNA, CCND1, MYC, BCL2, BAX, MMP9 | 2.67E-05 |
| hsa04151 | PI3K-Akt signaling pathway | 6 | CCND1, IRS1, MYC, BCL2, PCK1, BCL2L1 | 0.001536 |
| h_P53Pathway | P53 Signaling Pathway | 5 | PCNA, CCND1, GADD45A, BCL2, BAX | 7.72E-06 |
| hsa05220 | Chronic myeloid leukemia | 5 | BCR, CCND1, MYC, ABL1, BCL2L1 | 3.02E-05 |
| hsa04152 | AMPK signaling pathway | 5 | CCND1, IRS1, IRS2, PCK1, PPARGC1A | 2.45E-04 |
| hsa04110 | Cell cycle | 5 | PCNA, CCND1, GADD45A, MYC, ABL1 | 2.53E-04 |
| hsa04068 | FoxO signaling pathway | 5 | CCND1, IRS1, GADD45A, IRS2, PCK1 | 3.41E-04 |
| hsa05202 | Transcriptional misregulation in cancer | 5 | MEF2C, MYC, SIX1, MMP9, BCL2L1 | 7.86E-04 |
| hsa05166 | HTLV-I infection | 5 | PCNA, CCND1, MYC, BAX, BCL2L1 | 0.003689 |
| hsa05210 | Colorectal cancer | 4 | CCND1, MYC, BCL2, BAX | 5.17E-04 |
| hsa04920 | Adipocytokine signaling pathway | 4 | IRS1, IRS2, PCK1, PPARGC1A | 7.38E-04 |
| hsa05222 | Small cell lung cancer | 4 | CCND1, MYC, BCL2, BCL2L1 | 0.001299 |
| hsa04931 | Insulin resistance | 4 | IRS1, IRS2, PCK1, PPARGC1A | 0.002587 |
| hsa04722 | Neurotrophin signaling pathway | 4 | IRS1, BCL2, ABL1, BAX | 0.003489 |
| h_il2rbPathway | IL-2 Receptor Beta Chain in T cell Activation | 4 | IRS1, MYC, BCL2, BCL2L1 | 0.003877 |
| 127 | Mito-stress | 3 | BCL2, BAX, BCL2L1 | 0.002915 |
| 152 | Altered synaptic signalling-neurodegenerative disorders | 3 | BCL2, BAX, BCL2L1 | 0.002915 |
| hsa05219 | Bladder cancer | 3 | CCND1, MYC, MMP9 | 0.004992 |